CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Magnesium supplement (magnesium hydroxide/ -oxide) +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01118923
NCT01118923N/ACompleted
CompareCT.gov

Metacholine-provocation of Mablet-treated Asthmatics

University of Aarhus·interventional·Posted May 7, 2010·Updated Sep 4, 2013

In Brief

A clinical study evaluating Magnesium supplement (magnesium hydroxide/ -oxide) and Placebo for Asthma. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease. The aim of this part of the project is to study the effect of a daily magnesium supplement on the grade of bronchial hyperreactivity in asthmatics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesDenmark
CollaboratorsGunnar Kjems APS, GCP-unit at Aarhus University Hospital, Aarhus, Denmark, Aarhus University Hospital

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 7, 2010
Enrollment StartOct 1, 2010
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.2 years ago

Interventions

Magnesium supplement (magnesium hydroxide/ -oxide)dietary

3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS

Placebodietary

3 placebo-tablets daily for 12 weeks